Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7151133 | 0.93 | GNAI3 (0.38) | GNAI3GNAO1GNAI1SIGMAR1CTSK | |
| SCHEMBL13398353 | 0.89 | CTSK (0.34) | GNAI3GNAO1GNAI1SIGMAR1CTSK | |
| Pyridine SCHEMBL28175673 | 0.87 | ACACB (0.36) | GNAI3GNAO1GNAI1LIPEGAA | |
| SCHEMBL1576452 | 0.82 | CTSK (0.40) | CTSKLIPEGAAUSP2SMN1; SMN2 | |
| SCHEMBL477283 | 0.82 | LIPE (0.42) | CTSKLIPEGAAUSP2SMN1; SMN2 | |
| SCHEMBL694641 | 0.81 | LIPE (0.44) | CTSKLIPEGAACA1CA2 | |
| SCHEMBL7365934 | 0.81 | LIPE (0.44) | CTSKLIPEGAACA1CA2 | |
| SCHEMBL25935196 | 0.78 | CYP1A2 (0.35) | LIPEGAAUSP2MEN1KMT2A | |
| SCHEMBL25724325 | 0.78 | SMN1; SMN2 (0.53) | CTSKLIPEUSP2SMN1; SMN2CA1 | |
| SCHEMBL21882366 | 0.78 | CTSK (0.36) | CTSKLIPEUSP2SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| EP-4673445-A1 | STING AGONISTS CONTAINING BENZYLIC ALCOHOL AND BENZYLIC AMINE FUNCTIONAL GROUPS | BioNTech SE (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673439-A1 | STING AGONISTS CONTAINING HYDRAZIDE, HYDRAZINE, AND HYDROXAMIC ACID FUNCTIONAL GROUPS | BioNTech SE (DE) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025133654-A1 | NEW CRYPTATE-TYPE (BICYCLIC) CHELATORS AND THEIR USE AS LIGANDS FOR MN(II)-BASED MRI CONTRAST AGENTS, 52MN-BASED PET DIAGNOSTIC AGENTS, AND 64/67CU(II)-ISOTOPE-BASED PET DIAGNOSTIC AND THERAPEUTIC AGENTS | DEBRECENI EGYETEM (HU) | 2025-06-26 | — | — | WO | disclosed |
| CN-120025326-A | Heterocyclic compound of bifunctional chimera for targeting and degrading androgen receptor and application thereof | 广东东阳光药业股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119866217-A | Agent for restoring metal steady state containing malonic acid or derivative thereof | 牛津抗生素(制药)集团股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-27 | — | — | US | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025049804-A2 | AGENTS FOR THE TREATMENT OF NON-REPLICATING BACTERIA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1620459-A | Fused bicyclic pyrimidine derivatives | KYORIN SEIYAKU KK (JP) | 2005-05-25 | — | — | CN | disclosed |
| EP-1513531-A1 | BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Menarini Ricerche S.p.A. (IT) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003103671-A1 | BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | MENARINI RICERCHE S.P.A. (IT) | 2003-12-18 | — | — | WO | disclosed |
| US-6291464-B1 | POTENTIATION OF THE CHOLINERGIC ACTIVITY; THERAPEUTIC TREATMENT OF AMNESIA, DEMENTIA OR SENILE DEMENTIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6117870-A | USEFUL AS THERAPEUTIC DRUG OR PREVENTIVE DRUG OF ARTHRITIS AND RHEUMATISM DUE TO INCREASE OF BONE RESORPTION IN ADDITION TO BONE DISEASES SUCH AS OSTEOPOROSIS, HYPERCALCEMIA, AND PAGET'S DISEASE | FUJIREBIO KABUSHIKI KAISHA (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1008592-A2 | Cyclic amide derivatives which inhibit cathepsin K | Fujirebio Kabushiki Kaisha (JP) | 2000-06-14 | — | — | EP | disclosed |
| EP-0968201-A2 | NEW AMINOPIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998035951-A2 | NEW AMINOPIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-08-20 | — | — | WO | disclosed |
| EP-0541168-A1 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO. INC. (US) | 1993-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | KIF18B, KIF18A, KIF5B | GNAI3 1894/4885GNAO1 2689/4885GNAI1 1982/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | GNAI3 475/4885GNAO1 1456/4885GNAI1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.